Brinzolamide NEW
| Price | $30 | $58 | $89 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Brinzolamide | CAS No.: 138890-62-7 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Brinzolamide |
| Description | Brinzolamide (AL-4862) is a Carbonic Anhydrase Inhibitor. Its mechanism of action involves inhibiting the enzyme Carbonic Anhydrase. |
| In vitro | A 0.6 mg dose of Brinzolamide ophthalmic suspension reduces intraocular pressure in a dose-dependent manner in cynomolgus monkeys post-laser glaucoma surgery. Similarly, it lowers intraocular pressure in Dutch belted rabbits. Dosages of 1 mg/kg, 10 mg/kg, and 30 mg/kg of Brinzolamide prolong the sleep time induced by barbital in male CD-1 mice by 57%, 15%, and 35%, respectively. Less than 3% of Brinzolamide significantly increases both the percentage reduction and the mean decrease in intraocular pressure among patients with primary open-angle glaucoma or ocular hypertension compared to a placebo group. Additionally, a 2% Brinzolamide solution enhances optic nerve head blood flow and reduces intraocular pressure in resting Dutch belted rabbits. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 60 mg/mL (156.45 mM), Sonication is recommended. |
| Keywords | IOP | Brinzolamide | glaucoma | intraocular pressure | Carbonate dehydratase | inhibit | Inhibitor | atrial fluid | AL4862 | Carbonic Anhydrase | AL 4862 | carbonic anhydrase II |
| Inhibitors Related | Benzenesulfonamide | Urea | Cyclamic acid sodium | Orthanilamide | Tioxolone | Zonisamide | Histone acetyltransferase p300 Inhibitor 4c | EMAC10101d | pNNP | Trichlormethiazide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/10mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-07-19 | |
| $0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-11-01 | |
| $35.00/1kg |
Shanghai Chinqesen Biotechnology Co., Ltd.
|
2023-10-30 | ||
| $35.00/1kg |
Hebei Xinsheng New Material Technology Co., LTD.
|
2023-10-16 | ||
| $50.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-09-13 | |
| $0.00/1g |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-08-03 | |
| $100.00/1g |
Shijiazhuang Gantuo Biotechnology Co., Ltd
|
2023-03-10 | ||
| $0.00/25kg |
PNP Biotech Co. Ltd
|
2022-10-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY